AGC Biologics is deeply concerned and grieved about the situation in Ukraine. We sincerely hope that peaceful life will return to everyone as soon as possible. We also stand in partnership with our parent company, AGC Inc., in providing support for the safety and wellbeing of our Ukrainian colleagues and their families.
AGC Biologics Provides Aid to Ukraine
by Nick McDonald Published on 5/11/22 2:01 PM News
Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate
by Nick McDonald Published on 3/31/22 6:00 AM News
AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA Starting Material
by Press Release Published on 2/8/22 4:00 PM News, Company News, Partnership
AGC Biologics Names Regina Choi-Rivera General Manager of Boulder Facility
by Press Release Published on 1/18/22 1:15 PM News, Company News
I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project
by Nick McDonald Published on 12/13/21 5:00 PM News
AGC Biologics today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.
AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry
by Nick McDonald Published on 12/7/21 10:39 AM News
AGC Biologics today announced it won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.
4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab
by Press Release Published on 12/1/21 6:03 AM News, Company News
AGC Biologics to produce Procizumab for early and late clinical Phases at the company’s Chiba and Copenhagen facilities
AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer
by Press Release Published on 11/1/21 6:00 AM News
AGC Biologics Expands pDNA and mRNA Manufacturing Capacity
by Nick McDonald Published on 9/13/21 5:00 PM News
Seattle – September 13, 2021 – AGC Biologics today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site
by Matteo Pellegrino Published on 8/20/21 10:30 AM News